MARKET

BNTC

BNTC

Benitec Biopharma
NASDAQ

Real-time Quotes | Nasdaq Last Sale

2.940
+0.110
+3.89%
Closed 16:00 11/27 EST
OPEN
2.870
PREV CLOSE
2.830
HIGH
3.060
LOW
2.816
VOLUME
422.81K
TURNOVER
--
52 WEEK HIGH
17.42
52 WEEK LOW
2.520
MARKET CAP
12.95M
P/E (TTM)
-0.0181
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
The Daily Biotech Pulse: Amarin Surges On Vascepa Data, Mesoblast Rallies On Novartis Deal, Decision Day For Eiger
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Nov. 19)
Benzinga · 11/20 12:37
The Daily Biotech Pulse: Novartis Acquires Gene Therapy Company, Moderna's Japanese Vaccine Supply Deal
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 28)
Benzinga · 10/29 11:30
Benitec Biopharma Announces Closing of $11.5 Million Public Offering and Full Exercise of Underwriter's Option to Purchase Additional Shares
Benitec Biopharma Inc. (NASDAQ: BNTC) ("Benitec" or "the Company"), a development-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on the proprietary DNA-directed RNA interference ("ddRNAi") platform, today announced the closing
PR Newswire · 10/06 21:05
MYOK, TEF among premarket gainers
MyoKardia (MYOK) +59% as Bristol to acquire the company for $225/Share.Kosmos Energy (KOS) +50% as company closed a Gulf of Mexico facility with Beal Bank USA and Trafigura Trading LLC.Enlivex Therapeutics (ENLV) +49%.Corvus Pharmaceuticals
Seekingalpha · 10/05 12:28
Mid-Afternoon Market Update: Dow Falls 50 Points; IDT Shares Climb After Q4 Results
Toward the end of trading Friday, the Dow traded down 0.19% to 27,767 while the NASDAQ fell 1.92% to 11,108.78. The S&P also fell, dropping 0.63% to 3,359.64.
Benzinga · 10/02 19:22
LAC, VJET, MESO and PDLI among midday movers
Gainers: American Renal Associates (ARA) +68%.IDT (IDT) +37%.Nano-X Imaging (NNOX) +36%.Westwater Resources (WWR) +24%.voxeljet (VJET) +21%.Houghton Mifflin Harcourt (HMHC) +21%.ProPhase Labs (PRPH) +19%.Lithium Americas (LAC) +19%.Telenav (TNAV) +18%.Assured Guaranty (AGO) +17%.Losers: Benitec Biopharma (BNTC) -36%.Mesoblast
Seekingalpha · 10/02 16:47
Mid-Day Market Update: Nasdaq Down 2%; American Renal Associates Shares Jump
Midway through trading Friday, the Dow traded down 0.58% to 27,656.50 while the NASDAQ fell 2.02% to 11,097.21. The S&P also fell, dropping 1% to 3,347.06.
Benzinga · 10/02 16:14
Aduro Biotech, American Renal Associates leads healthcare gainers; Benitec Biopharma, Mesoblast among major losers
Gainers: Aduro Biotech (ADRO) +442%, American Renal Associates (ARA) +69%, Nano-X Imaging (NNOX) +38%, CTI BioPharma (CTIC) +18%, ProPhase Labs (PRPH) +16%.Losers: Benitec Biopharma (BNTC) -36%, Mesoblast (MESO) -36%, Arcutis Biotherapeutics (ARQT) -14%, PDL BioPharma (PDLI) -13%, Electromed (ELMD) -12%.
Seekingalpha · 10/02 14:56
More
Forecast
EPSBVPSCFPS
Actual (K USD)
Estimate (K USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of BNTC. Analyze the recent business situations of Benitec Biopharma through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 1 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average BNTC stock price target is 14.00 with a high estimate of 14.00 and a low estimate of 14.00.
EPS
Institutional Holdings
Institutions: 15
Institutional Holdings: 239.26K
% Owned: 5.43%
Shares Outstanding: 4.41M
TypeInstitutionsShares
Increased
1
5.50K
New
4
15.89K
Decreased
1
998
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+3.18%
Pharmaceuticals & Medical Research
+1.72%
Key Executives
Chairman/Director
Jerel Banks
Chief Executive Officer/Secretary
Gregory West
Chief Financial Officer
Bryan Dulhunty
Chief Scientific Officer
Michael Graham
Secretary
Oliver Kidd
Director
Kevin Buchi
Non-Executive Director
Megan Boston
Non-Executive Director
Peter Francis
  • Dividends
  • Splits
  • Insider Activity
Declaration Date
Dividend Per Share
Ex-Div Date
--
Dividend USD 0.002929
06/01/2018
  • All
  • Financials
  • Insiders
More
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About BNTC
Benitec Biopharma Inc. formerly Benitec Biopharma Limited, incorporated on April 7, 1995, a is a clinical-stage biotechnology company. The Company focused on the development of genetic medicines. The Company is developing a therapeutic technology platform that combines Ribonucleic acid (RNA) interference with gene therapy for providing sustained, long-lasting silencing of disease-causing genes from a single administration. The Company is using this technology, called Deoxyribonucleic acid (DNA)-directed RNA interference, or ddRNAi, to develop product candidates in chronic and life-threatening human disease areas including orphan disease and infectious disease. Benitec endeavors to develop and commercialize BB-301 for the treatment of Oculopharyngeal Muscular Dystrophy, or OPMD. The Company’s pipeline includes Oculopharyngeal Muscular Dystrophy (OPMD) Hepatitis B BB-103.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Benitec Biopharma Inc stock information, including NASDAQ:BNTC real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BNTC stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading BNTC stock methods without spending real money on the virtual paper trading platform.